.Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01C_HypothalamicHormones.H01CC53_ElagolixEstradiolAndNore.ElagolixEstradiolAndNore .Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01C_HypothalamicHormones.H01CC53_ElagolixEstradiolAndNore.ElagolixEstradiolAndNore| name: | ElagolixEstradiolAndNorethisterone | |
| ATC code: | H01CC53 | route: | oral |
| compartments: | 1 | |
| dosage: | 300 | mg |
| volume of distribution: | 120 | L |
| clearance: | 12 | L/h |
| other parameters in model implementation | ||
Elagolix, estradiol, and norethisterone are combined in an oral contraceptive and hormone therapy regimen, often studied for the treatment of endometriosis-associated pain and/or uterine fibroids. Elagolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol is a form of estrogen, and norethisterone (also known as norethindrone) is a progestin. The combination is used to modulate hormonal balance, reduce bone loss risk, and mitigate hypoestrogenic symptoms in women taking elagolix.
Estimated pharmacokinetic parameters for healthy adult women (average age 18-49), based on published monograph pharmacokinetics of the individual components, as there are currently no comprehensive published human PK models for the fixed-dose combination.